RE:RE:RE:RE:RE:RE:Dan and next weekSorry Mugs. going to disagree with you there. To augment the regimen with another pain med will not solve anything because all these med elevate the liver enzymes. And we still havent found the intermediary compound thats responsible for all these effects, to explore potential interactions with other analgesic meds.
I would argue that once they find the quickest way to get this drug to market, the off label use for chronic pain will skyrocket and any liver enzyme elevation will be managed by your PHC provider. As is common practice in the field.
Like I have mentioned before, the sad truth in medicine is that ALL medications, in the long term, negatively affects the liver, especially in the NSAID and antipyretic class of medications. Despite the black box label for liver issues with anti pyretics, theyre still on the market but they are all managed. If it is as dire as some people make it out to be, they would've pulled the drugs out of the market like Rofecoxib.
Perfection is the enemy of the good, after all. The main obstacle now is management competency. We need fixed timelines, catalysts, and avoiding dilution. I will admit they have assured investors with the phrase "cash on hand" only to raise and dilute shares later. I want to see financials and cash burn with respect to likelihood of another raise/dilution.
GLTA
MrMugsy wrote: Right - I think the release says it as "dosing regimen for OA indication requires additional investigation." Finding the right amount of painkiller while keeping liver enzymes at bay over the longrun is the challenge. Something that doesn't confuse the liver with external H2S while it's also trying to produce its own.
Let's say they come so close but just can't find the right combo. Worst case - I would like to see an attempt to supplement other pain regimens with OTENA. Not saying we need to go that far ... but ... there seems to be a worst-case chronic scenario (at least in my head).
While we wait for chronic tweaking - we attack on the acute front. In my opinion.
Inthepez wrote: Failure is a strong word. GI safety: excellent. Analgesia: excellent.
This liver enzyme elevation is a dosing issue.
MasterAlgae wrote: Nor is the fault of the CEO that the lead drug failed.
The CEO got a boat-load of after-tax money from the retail investor - that is a success, job done.
Most of us are not happy with the failure but that's the risk.
Forestview wrote: You should email him and vent your frustrations directly to him. Doing it here is pointless.
dan@antibethera.com
Layth1990 wrote: He still can save the company if he resigns